Article Text
Statistics from Altmetric.com
The development of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) leads to significant morbidity and mortality.1 ILD impacts approximately 10% of patients with RA and even higher percentages have subclinical ILD.2 3 Despite the clinical impact of ILD in a patient with RA, this comorbidity is poorly understood.
Recently, we and others have leveraged our understanding of idiopathic pulmonary fibrosis (IPF) to better understand RA-ILD given similarities in demographics, radiology, pathology, natural history and more recently genetics.4 Looking to large, unbiased ’omic-based analyses, including proteomics, to further our understanding of RA-ILD is a logical next step. These approaches could identify novel and shared biomarkers …
Footnotes
Twitter @scott_matson
Contributors SM and JSL contributed equally to this editorial.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; externally peer reviewed.